ReShape Lifesciences (RSLS) Competitors

ReShape Lifesciences (NASDAQ:RSLS) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.

Which has better valuation and earnings, RSLS or ABT?

Abbott Laboratories has higher revenue and earnings than ReShape Lifesciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$8.68M	0.37	-$11.39M	N/A	N/A
Abbott Laboratories	$40.11B	5.05	$5.72B	$3.29	35.50

Which has more volatility & risk, RSLS or ABT?

ReShape Lifesciences has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Does the media favor RSLS or ABT?

In the previous week, Abbott Laboratories had 68 more articles in the media than ReShape Lifesciences. MarketBeat recorded 68 mentions for Abbott Laboratories and 0 mentions for ReShape Lifesciences. Abbott Laboratories' average media sentiment score of 1.33 beat ReShape Lifesciences' score of 0.00 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
ReShape Lifesciences	Neutral
Abbott Laboratories	Positive

Is RSLS or ABT more profitable?

Abbott Laboratories has a net margin of 13.99% compared to ReShape Lifesciences' net margin of -86.36%. Abbott Laboratories' return on equity of 20.18% beat ReShape Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-86.36%	-179.83%	-91.48%
Abbott Laboratories	13.99%	20.18%	10.84%

Does the MarketBeat Community favor RSLS or ABT?

Abbott Laboratories received 538 more outperform votes than ReShape Lifesciences when rated by MarketBeat users. Likewise, 69.75% of users gave Abbott Laboratories an outperform vote while only 66.11% of users gave ReShape Lifesciences an outperform vote.

Company	Underperform	Outperform
ReShape Lifesciences	Outperform Votes 398 66.11%	Underperform Votes 204 33.89%
Abbott Laboratories	Outperform Votes 936 69.75%	Underperform Votes 406 30.25%

Do analysts rate RSLS or ABT?

Abbott Laboratories has a consensus price target of $131.93, indicating a potential upside of 12.97%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than ReShape Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73

Do insiders and institutionals hold more shares of RSLS or ABT?

22.1% of ReShape Lifesciences shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.1% of ReShape Lifesciences shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Abbott Laboratories beats ReShape Lifesciences on 15 of the 16 factors compared between the two stocks.